Vincent Ma, MD

Hematology, Medical Oncology and Palliative Care
Assistant Professor (CHS)
Clinical Science Center
600 Highland Ave K4/550
Madison WI 53792-0001
(608) 263-5391

Follow Dr. Ma:

X icon  LinkedIn icon


  • University of Nevada School of Medicine, Reno, Nevada – MD
  • University of Michigan Health System, Ann Arbor, Michigan – Internal Medicine Residency
  • University of Michigan Rogel Cancer Center, Ann Arbor, Michigan – Hematology and Oncology Fellowship

Professional Activities

Dr. Vincent Ma is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine and a faculty affiliate of the Department of Dermatology.  Dr. Ma is a member of the American Society of Clinical Oncology (ASCO), the Society for Immunotherapy of Cancer (SITC), the Society of Melanoma Research and the ECOG-ACRIN Cancer Research Group. He is a recipient of the 2021 ASCO Conquer Cancer Merit Award, the 2021 Excellence in Clinical Research Award at Michigan Medicine Rogel Cancer Center, the 2022 40 Under 40 in Cancer Award, and is a KL2 Scholar. He currently serves as co-chair of the Big Ten Cancer Research Consortium Melanoma/Cutaneous Oncology Clinical Trial Working Group and is the Immuno-Oncology therapeutics lead in the Early Phase Oncology Therapeutics Program at the University of Wisconsin.

Clinical Specialties

Dr. Ma’s primary clinical interests are the diagnosis, treatment, and surveillance of melanoma and other advanced stage cutaneous malignancies, including Merkel cell carcinoma, basal cell carcinoma, and cutaneous squamous cell carcinoma. He also has interests in the management of immune-related adverse events from immune checkpoint inhibitor therapy.

Research Interests

View Dr. Vincent Ma's publications on NCBI MyBibliography

Dr. Ma’s research focus is on optimizing therapeutic strategies in melanoma and other advanced cutaneous malignancies with an emphasis in early phase clinical trial investigation involving immunotherapy and molecular targeted agents. He has clinical trial experience, serving as principal and sub-investigator on several industry sponsored studies. He is an active member of the UW Carbone Cancer Phase 1 group and Melanoma Disease Oriented Team group.